Indegene Ltd
It is a digital-first, life sciences commercialization company. It helps biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way.
- Market Cap ₹ 13,733 Cr.
- Current Price ₹ 574
- High / Low ₹ 660 / 469
- Stock P/E 41.0
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 29.0 %
- ROE 26.9 %
- Face Value ₹ 2.00
Pros
- Company has delivered good profit growth of 88.5% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 29.2%
Cons
- Working capital days have increased from 71.1 days to 152 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Miscellaneous Industry: Miscellaneous
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| 553 | 643 | 966 | 1,665 | 2,306 | 2,590 | |
| 511 | 499 | 736 | 1,378 | 1,910 | 2,084 | |
| Operating Profit | 42 | 144 | 230 | 287 | 396 | 505 |
| OPM % | 8% | 22% | 24% | 17% | 17% | 20% |
| 7 | -102 | -3 | -21 | 58 | 79 | |
| Interest | 6 | 9 | 7 | 6 | 31 | 49 |
| Depreciation | 17 | 19 | 26 | 33 | 60 | 76 |
| Profit before tax | 26 | 14 | 195 | 226 | 363 | 459 |
| Tax % | 45% | 191% | 23% | 28% | 27% | 27% |
| 14 | -12 | 149 | 163 | 266 | 337 | |
| EPS in Rs | 89.98 | -40.20 | 951.96 | 937.73 | 11.99 | 15.14 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 36% |
| 3 Years: | 39% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 88% |
| 3 Years: | 32% |
| TTM: | 26% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 29% |
| Last Year: | 27% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0 | 0 | 0 | 0 | 44 | 44 |
| Reserves | 73 | -105 | 324 | 764 | 1,019 | 1,385 |
| Preference Capital | 79 | 315 | 0 | 0 | 0 | |
| 69 | 168 | 51 | 66 | 503 | 490 | |
| 187 | 537 | 220 | 524 | 638 | 627 | |
| Total Liabilities | 329 | 600 | 596 | 1,353 | 2,204 | 2,546 |
| 104 | 119 | 86 | 138 | 664 | 646 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 13 | 0 | 120 | 614 | 796 |
| 225 | 468 | 510 | 1,096 | 926 | 1,103 | |
| Total Assets | 329 | 600 | 596 | 1,353 | 2,204 | 2,546 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| 65 | 22 | 172 | 297 | 130 | 508 | |
| -18 | -16 | -81 | -158 | -896 | -327 | |
| -21 | 136 | -132 | 233 | 333 | -66 | |
| Net Cash Flow | 25 | 143 | -40 | 373 | -433 | 114 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| Debtor Days | 60 | 127 | 108 | 97 | 102 | 78 |
| Inventory Days | ||||||
| Days Payable | ||||||
| Cash Conversion Cycle | 60 | 127 | 108 | 97 | 102 | 78 |
| Working Capital Days | 23 | 64 | 53 | 16 | 45 | 152 |
| ROCE % | 37% | 55% | 46% | 33% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
1m - Institute of Science and Ignite Life Science Foundation announce strategic collaboration with Indegene to advance scientific discoveries in India.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
19h - Of Schedule of Investor / Analyst meeting under the SEBI (LODR), Regulations, 2015
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
4 Jun - Transcript of the Q4FY24 earnings call on the financial results for the quarter and financial year ended March 31, 2024
-
Opening Of Trading Window
31 May - Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company''s Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, …
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
31 May - Copies of the newspaper advertisement published in Financial Express (English) and Vishwavani (Kannada) today, relating to audited financial results for quarter and financial year ended …
Concalls
-
Jun 2024TranscriptPPT
Business Divison[1]
A) Enterprise Commercial Solutions aids life science companies in optimizing digital marketing operations, driving scale efficiency, and implementing technology-enabled personalization strategies for engagement with HCPs, patients, and operations.